OS and RFS stratified by proposed scoring system. Kaplan-Meier survival curves for OS (A) and RFS (B) in AML patients based on our new scoring system (P < .001 for both OS and RFS). AML patients were grouped according to our scoring system based on the DNMT3A mutation and 8 other prognostic markers (ie, age, WBC count at diagnosis, and CEBPA^{double-mutation}, NPM1/FLT3-ITD, IDH2, DNMT3A, WT1, and AML1/RUNX1 mutations). A score of −1 was assigned for each parameter associated with a favorable outcome (ie, CEBPA^{double-mutation}, IDH2 mutation, and NPM1⁺/FLT3-ITD⁻); a score of +1 was assigned for each factor associated with an adverse outcome (ie, older age, higher WBC counts at diagnosis, and DNMT3A, WT1, and AML1/RUNX1 mutations). The karyotypes were stratified into 3 groups (+2, unfavorable; +1, intermediate; and 0, favorable). The algebraic summation of these scores for each patient was the final score. The 12 patients without chromosome data were not included in the analysis.